Ocular Therapeutix (NSDQ:OCUL) is looking to raise $40 million through a public stock offering, according to a prospectus filed with the federal Securities & Exchange Commission this week.
The Bedford, Mass.-based company said it inked a controlled equity offering sales agreement with Cantor Fitzgerald & Co., and agreed to pay Cantor Fitzgerald commissions of up to 3% of the process from the sales of the shares for it services.
Get the full story at our sister site, Drug Delivery Business News.
The post OCUL registers for $40m stock sale appeared first on MassDevice.